Source: Eur Respir J, 59 (3) 2004306; 10.1183/13993003.04306-2020



Rating:

Share or cite this content

Citations should be made in the following way:
Rania Dagher, Varsha Kumar, Alan M. Copenhaver, Sandra Gallagher, Mahboobe Ghaedi, Jonathan Boyd, Paul Newbold, Alison A. Humbles, Roland Kolbeck. Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity. Eur Respir J, 59 (3) 2004306; 10.1183/13993003.04306-2020

Member's Comments

No comment yet.

Related content which might interest you: Mechanisms leading to the bronchorelaxant synergy of ICS/LABA/LAMA combination Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agent Source: Annual Congress 2010 - Models of airways disease Year: 2010 Human Airway Trypsin-like protease exerts potent anti-fibrotic role in vivo. Source: International Congress 2017 – Rare diseases Year: 2017 Novel inhibitory effect on 5-lipoxygenase activity by montelukast. Evidence for a noncompetitive mode of action Source: Eur Respir J 2004; 24: Suppl. 48, 96s Year: 2004 Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018 Year: 2019 Essential role of HDACs in the anti-inflammatory actions of IFN-γ in human ASM cells Source: Eur Respir J 2007; 30: Suppl. 51, 690s Year: 2007 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Role of altered immune response in CF and implication for antiinflammatory therapies Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease Year: 2012 In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 A novel mechanism of autotaxin-mediated cell signaling that is independent of catalytic activity and inhibited by ziritaxestat Source: Virtual Congress 2021 – Pathogenic progress in airway diseases Year: 2021 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Targeting metabolic reprogramming as a novel anti-fibrotic strategy Source: International Congress 2019 – Metabolic alterations as a driver of chronicity in lung disease Year: 2019 Anti-oxidative and anti-inflammatory effects of Xanthorrhizol on aeroallergens-induced biological responses in vitro and ex vivo Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 The mechanisms of anti-inflammatory action of bronchodilators Source: Annual Congress 2013 –COPD: experimental biology Year: 2013 The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Enhanced endothelial barrier protective and anti-inflammatory effects by synthetic iloprost-conjugated phospholipid. Source: International Congress 2018 – Triggers of acute lung injury: mechanical ventilation and oxygen levels Year: 2018